KPCM
ATRS

Kings Point Capital Management’s Antares Pharma, Inc. ATRS Stock Holding History

Kings Point Capital Management’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-47,500
Closed -$223K – 520
2019
Q4 		$223K Buy
47,500
+7,500
+19% +$30.7K 0.03% 172
2019
Q3 		$134K Buy
+40,000
New +$132K 0.02% 195

Other funds holding ATRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Kings Point Capital Management's ATRS Position: Q1 2020 in Review

Kings Point Capital Management sold out of Antares Pharma, Inc. (ATRS) in Q1 2020, closing a stake of 47,500 shares — an estimated $223K sold.

Kings Point Capital Management first reported a position in ATRS in Q3 2019 and held it in 2 quarters. The position peaked at $223K in Q4 2019. 154 funds tracked by Wall St. Rank hold ATRS as of Q1 2020.

  • Kings Point Capital Management reported no remaining Antares Pharma, Inc. position as of Q1 2020 after selling out during the quarter.
  • Kings Point Capital Management sold 47,500 Antares Pharma, Inc. shares in Q1 2020, an estimated $223K.
  • Kings Point Capital Management first reported a position in Antares Pharma, Inc. in Q3 2019 and held it in 2 quarters.
  • Kings Point Capital Management's Antares Pharma, Inc. position peaked at $223K in Q4 2019.
  • 154 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q1 2020.

Based on Kings Point Capital Management's 13F filing for Q1 2020, filed 14 May 2020.